Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders

被引：15
|
作者：
Yoon, David S. [1 ]
Wu, Shung C. [1 ]
Seethala, Ramakrishna [2 ]
Golla, Rajasree [2 ]
Nayeem, Akbar [3 ]
Everlof, John G. [4 ]
Gordon, David A. [5 ]
Hamann, Lawrence G. [1 ]
Robl, Jeffrey A. [1 ]
机构：
[1] Bristol Myers Squibb Co, Res & Dev, Dept Chem, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Res & Dev, Lead Evaluat, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Res & Dev, CADD, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Res & Dev, PCO Discovery Pharmaceut, Princeton, NJ 08543 USA
[5] Bristol Myers Squibb Co, Res & Dev, Dept Biol, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 21期
关键词：
11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1); Enzyme inhibitor; Pyridyl sulfonamide; Type-2; diabetes; SELECTIVE INHIBITORS; VISCERAL OBESITY; POTENT; HYPERGLYCEMIA; DESIGN; MODEL; MICE;
D O I：
10.1016/j.bmcl.2014.09.012
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A previous disclosure from this lab highlighted the discovery of pyridyl amides as potent 11 beta-HSD1 inhibitors. In order to build additional novelty and polarity into this chemotype, replacement of the hydrogen-bonding carbonyl (CO) pharmacophore with the bioisosteric sulfonyl (SO2) group was examined. Despite initial comparisons suggesting the corresponding sulfonamides exhibited weaker activity versus their carbonyl counterparts, further optimization was performed in an effort to identify various potent and unique leads for the program. Judicious incorporation of polar moieties resulted in the identification of compounds with enhanced potency and lipophilicity profiles, resulting in leads with superior aqueous solubility and liver microsomal stability. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5045 / 5049
页数：5
相关论文
共 50 条
  • [1] 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity
    Hughes, Katherine A.
    Webster, Scott P.
    Walker, Brian R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (04) : 481 - 496
  • [2] Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
    Ryu, Je Ho
    Kim, Shinae
    Han, Hye Young
    Son, Hyun Joo
    Lee, Hyun Jung
    Shin, Young Ah
    Kim, Jae-Sun
    Park, Hyeung-geun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 695 - 700
  • [3] Synthesis and optimization of picolinamide derivatives as a novel class of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors
    Ryu, Je Ho
    Kim, Shinae
    Lee, Jung A.
    Han, Hye Young
    Son, Hyun Joo
    Lee, Hyun Jung
    Kim, Yong Hyuk
    Kim, Jae-Sun
    Park, Hyeung-geun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (08) : 1679 - 1683
  • [4] Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
    Sun, Daqing
    Wang, Zhulun
    Cardozo, Mario
    Choi, Rebekah
    DeGraffenreid, Michael
    Di, Yongmei
    He, Xiao
    Jaen, Juan C.
    Labelle, Marc
    Liu, Jinsong
    Ma, Ji
    Miao, Shichang
    Sudom, Athena
    Tang, Liang
    Tu, Hua
    Ursu, Stefania
    Walker, Nigel
    Yan, Xuelei
    Ye, Qiuping
    Powers, Jay P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (05) : 1522 - 1527
  • [5] Discovery of Adamantyl Ethanone Derivatives as Potent 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors
    Su, Xiangdong
    Pradaux-Caggiano, Fabienne
    Thomas, Mark P.
    Szeto, Michelle W. Y.
    Halem, Heather A.
    Culler, Michael D.
    Vicker, Nigel
    Potter, Barry V. L.
    CHEMMEDCHEM, 2010, 5 (07) : 1026 - 1044
  • [6] Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)
    Scott, James S.
    Goldberg, Frederick W.
    Turnbull, Andrew V.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4466 - 4486
  • [7] Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1
    Tice, Colin M.
    Zhao, Wei
    Krosky, Paula M.
    Kruk, Barbara A.
    Berbaum, Jennifer
    Johnson, Judith A.
    Bukhtiyarov, Yuri
    Panemangalore, Reshma
    Scott, Boyd B.
    Zhao, Yi
    Bruno, Joseph G.
    Howard, Lamont
    Togias, Jennifer
    Ye, Yuan-Jie
    Singh, Suresh B.
    McKeever, Brian M.
    Lindblom, Peter R.
    Guo, Joan
    Guo, Rong
    Nar, Herbert
    Schuler-Metz, Annette
    Gregg, Richard E.
    Leftheris, Katerina
    Harrison, Richard K.
    McGeehan, Gerard M.
    Zhuang, Linghang
    Claremon, David A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (22) : 6725 - 6729
  • [8] 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors Still Improve Metabolic Phenotype in Male 11β-HSD1 Knockout Mice Suggesting Off-Target Mechanisms
    Harno, Erika
    Cottrell, Elizabeth C.
    Yu, Alice
    DeSchoolmeester, Joanne
    Gutierrez, Pablo Morentin
    Denn, Mark
    Swales, John G.
    Goldberg, Fred W.
    Bohlooly-Y, Mohammad
    Andersen, Harriet
    Wild, Martin J.
    Turnbull, Andrew V.
    Leighton, Brendan
    White, Anne
    ENDOCRINOLOGY, 2013, 154 (12) : 4580 - 4593
  • [9] Discovery of cyclicsulfonamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitors
    Kim, Se Hoan
    Ramu, Ravirala
    Kwon, Sung Wook
    Lee, Su-Hee
    Kim, Chi Hyun
    Kang, Seung Kyu
    Rhee, Sang Dal
    Bae, Myung Ae
    Ahn, Sung Hoon
    Ha, Duck Chan
    Cheon, Hyae Gyeong
    Kim, Ki Young
    Ahn, Jin Hee
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (03) : 1065 - 1069
  • [10] Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome
    Richards, Steven
    Sorensen, Bryan
    Jae, Hwan-Soo
    Winn, Marty
    Chen, Yixian
    Wang, Jiahong
    Fung, Steven
    Monzon, Katina
    Frevert, Ernst U.
    Jacobson, Peer
    Sham, Hing
    Link, J. T.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) : 6241 - 6245
12345